Clinical trial · Observational
Dysregulated Tyrosine Kinase Signaling in Leukemia
NCT00277056CI-TRIAL-00073756terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This is not a clinical trial and was entered in the system in error.
Summary
Brief summary (as posted)
Dysregulated Tyrosine Kinase Signaling in Leukemia
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have newly diagnosed or relapsed leukemia. * Patients must sign an informed consent. * Patients will not be excluded if they are receiving chemotherapy. * Patients with CML, AML, ALL, T/NK leukemia, myelodysplasia, or myeloproliferative disorders will be eligible. * Patients must be =\> 18 years of age.
References
Publications (0)
Data not yet available
No reference posted for this study.